Ardelyx, Inc. reported unaudited U.S. net product sales of IBSRELA and XPHOZAH totaling approximately $54 million and $57 million for Q4 2024, respectively, with full-year sales of about $158 million and $161 million; the company also had around $250 million in cash and investments as of December 31, 2024.